Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...